This article is more than 5 years old. Information may no longer be current.
Once-daily NSAID regimen minimizes ocular inflammation, pain after cataract surgery
Ophthalmology. 2011;118(11):2120-2127.
Click Here to Manage Email Alerts
A single daily dose of bromfenac ophthalmic solution reduced pain and inflammation after cataract surgery, a large study found.
"Patients may find that dosing once daily offers greater convenience, especially when they need to take multiple medications," the study authors said.
Four randomized, double-masked, vehicle- or active-controlled clinical trials undertaken at 134 U.S. ophthalmic clinics included 872 subjects; 584 eyes were randomized to undergo treatment with Bromday (bromfenac 0.09%, Ista Pharmaceuticals) and 288 eyes were randomized to receive placebo. All subjects were age 18 years or older.
Mean patient age was 68.9 years in the bromfenac group and 68.7 years in the placebo group.
Subjects received bromfenac or placebo once daily starting 1 day before surgery and continuing 14 days after surgery. Safety and efficacy of treatment were gauged on days 1, 3, 8, 15 and 22.
Study results showed that 51.1% of subjects in the bromfenac group and 27.4% of subjects in the placebo group had cleared ocular inflammation at 15 days. The between-group difference was statistically significant (P < .0001).
Significantly more patients in the bromfenac group were pain free than in the placebo group at 1, 3, 8 and 15 days (P < .0001).
The incidence of adverse events was 55% in the placebo group and 35.1% in the bromfenac group (P < .0001), the authors said.